Incidence of Interstitial Lung Disease in Patients With Rheumatoid Arthritis Treated With Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs

IMPORTANCE: Current data are lacking regarding the risk of biologic and targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) use on the development of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA). OBJECTIVE: To determine the risk of developing ILD in pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Baker, Matthew C., Liu, Yuhan, Lu, Rong, Lin, Janice, Melehani, Jason, Robinson, William H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028485/
https://www.ncbi.nlm.nih.gov/pubmed/36939701
http://dx.doi.org/10.1001/jamanetworkopen.2023.3640

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028485/
https://www.ncbi.nlm.nih.gov/pubmed/36939701
http://dx.doi.org/10.1001/jamanetworkopen.2023.3640

Ejemplares similares